OPERATOR: Good day, ladies and gentlemen, and welcome to the Q3 2008 Nabi Biopharmaceuticals earnings call. My name is Colby, and I will be your coordinator for today. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of this conference. (OPERATOR INSTRUCTIONS). And as a reminder, this conference is being recorded for replay purposes. I would now like to turn the presentation over to your host for today's call, Mr. Gregory Fries, Manager of Investor Relations. Please proceed, sir.
GREGORY FRIES, MANAGER OF IR, NABI BIOPHARMACEUTICALS: Thank you Colby. Good afternoon, and thank you all for joining us today. As a reminder, the news release announcing our third quarter 2008 financial results is available on our website at www.nabi.com. I'd also like to remind that today's call may include forward-looking statements. These forward-looking statements and related risk factors are more fully disclosed and discussed in our annual report on Form 10-K for the fiscal year ended December 29, 2007, and in our quarterly report on Form 10Q four the quarter ended June 28, 2008, both filed with the Securities & Exchange Commission. More information is also available on our website at www.nabi.com.
At this time I would like to turn the call over to Dr. Raafat Fahim, President and Chief Executive Officer of Nabi. Raafat?
RAAFAT FAHIM, PRESIDANT & CEO, NABI BIOPHARMACEUTICALS: Thank you, Greg, and thanks to all of you for participating in this call. Joining me for today's call is Dr. Paul Kessler, Senior Vice President of Clinical, Medical and Regulatory Affairs, and Mr. (Ron Cosack), Controller and Chief Accounting Officer. On this call, I'll be talking to you about our third quarter financial results. However, before we review the financial results, I would like to discuss a few other subjects.
The progress of our strategic alternatives process is obviously of great interest to our shareholders. As you know, this process is focused on, but not limited to, the sale or merger of the company or the outlicensing of our product candidates. We remain focused on this process and we continue to see interest in Nabi from several parties. This interest continues, despite the overall market turmoil in recent months.
As we previously indicated, we do not intend to discuss details until we have a definitive agreement and Nabi's Board of Directors authorizes such communication. Our primary objective is to maximize the value of our assets for the benefit of all of our shareholders through either a sale of merger of the company, or by developing strategic partnerships for our development pipeline products. As you may know, we recently …